DhMotC, an inhibitor of tumor cell invasion [19], also inhibits sphingolipid biosynthesis and genes of the sphingolipid biosynthesis pathway show dhMotC-induced haploinsufficiency [6]. Interestingly, suloctidil was recently shown to inhibit acid sphingomyelinase, a lysosomal enzyme catalyzing the degradation of sphingolipids and generating ceramide, which can be metabolised selleck into sphingosine [20]. These results show that the majority of chemicals that inhibit yeast growth do not require functional mitochondria to exert their effect but that 3 Temsirolimus ic50 compounds affecting sphingolipid metabolism all

require functional mitochondria to inhibit growth. We then further explored the requirement for functional mitochondria in the mechanism of action of 1 of these chemicals, dhMotC, using genetic screens and biological assays. Prolonged exposure to dhMotC kills yeast Growth-inhibitory compounds can reversibly prevent cell proliferation (cytostatic activity) or induce death (cytocidal activity). To distinguish between these outcomes, cells this website were exposed to inhibitory concentrations of dhMotC in liquid culture for different times and equal cell numbers were plated onto drug-free agar plates for 2 days at 30°C. Cells exposed to dhMotC for 1, 3

or 6 hours all formed the same number of colonies as untreated cultures. However, exposure to dhMotC for 20 h resulted in no colony growth (Figure 2). These Exoribonuclease observations show that dhMotC exposure initially triggers a reversible growth arrest that eventually leads to cell death after longer exposure. Figure 2 Viability test of FY1679-28C/TDEC yeast strain exposed to dhMotC. Short exposure times result in reversible growth inhibition. There is no observable

growth after long drug exposure. DhMotC sensitivity suppressor screen reveals genes involved in mitochondrial function Screens using increased gene dosage, relying on the assumption that increased levels of a protein targeted by a drug increase resistance to the drug, can help identify specific drug targets [9]. Drug sensitivity suppressor screens can be carried out with pooled genomic library transformants, leading to enrichment of resistant strains and depletion of hypersensitive strains, relative to untreated pools. Analysis of relative strain sensitivity is performed by hybridization of labelled DNA to an oligonucleotide tag array [21]. A pooled collection of yeast strains expressing genes from a random genomic DNA fragment library was exposed to dhMotC and resistant strains were identified. Similar experiments were carried out using 3 close structural analogues (Figure 3). Syntenic regions (i.e.